BioRegenx

BioRegenx, Inc. develops a social media content management platform. The company is headquartered in Chattanooga, Tennessee and currently employs 6 full-time employees. The company went IPO on 2000-11-06. The Company’s subsidiaries include DocSun BioMedical Holdings, Inc. (DocSun), Microvascular Health Solutions, LLC (MVHS), MyBodyRx, LLC (MyBodyRx), NuLife Sciences, Inc. (NuLife) and Findit Ai Connect, Inc. (Findit Ai). DocSun combines three technologies in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an individual's heartbeat without touch, and photoplethysmography, a method that uses light to track the flow of blood. MVHS specializes in research, product development, sales, and education, notably producing the patented Endocalyx Pro dietary supplement. MVHS also manufactures and distributes the patented GlycoCheck software and Class 1 medical devices. DocSun is also developing an app for NuLife, TruScan.Ai mobile app/Website.